RSS

dolutegravir/rilpivirine

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the European Commission has granted marketing authorisation for Juluca (dolutegravir/rilpivirine) — a two-drug regimen, once-daily, single pill for the treatment of HIV-1. more

News